
CSPHF
Healthcare · Biotechnology · $1.10B market cap
$0.68900.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2024
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Jun 30, 2021 | Time not confirmed | 0.00 | -0.05 | — |
| Mar 25, 2021 | Before the open | 0.00 | -0.05 | — |
| Dec 31, 2020 | Time not confirmed | 0.00 | -0.04 | — |
| Aug 18, 2020 | Before the open | 0.00 | -0.04 | — |
| Jun 30, 2020 | Time not confirmed | 0.00 | -0.05 | — |
| Mar 26, 2020 | Before the open | 0.00 | -0.05 | — |
| Dec 31, 2019 | Time not confirmed | 0.00 | -0.08 | — |
| Aug 14, 2019 | After the close | 0.00 | -0.08 | — |
| Jun 30, 2019 | Time not confirmed | 0.00 | -0.10 | — |
| Mar 22, 2019 | Before the open | 0.00 | -0.10 | — |
| Dec 31, 2018 | Time not confirmed | 0.00 | -0.12 | — |
| Jun 30, 2018 | Time not confirmed | 0.00 | -0.10 | — |
| Mar 31, 2018 | Time not confirmed | 0.00 | -0.11 | — |
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma,…